One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study
Abstract Introduction The aim of this study was to compare the efficacy of the treat-and-extend (TAE) regimen versus the pro re nata (PRN) regimen in patients with bevacizumab-resistant diabetic macular edema (DME) treated with aflibercept, with or without adjunctive laser therapy. Methods Ninety-on...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-11-01
|
| Series: | Ophthalmology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40123-024-01067-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544931702734848 |
|---|---|
| author | Zubeyir Yozgat Mehmed Ugur Isik Mehmet Cem Sabaner |
| author_facet | Zubeyir Yozgat Mehmed Ugur Isik Mehmet Cem Sabaner |
| author_sort | Zubeyir Yozgat |
| collection | DOAJ |
| description | Abstract Introduction The aim of this study was to compare the efficacy of the treat-and-extend (TAE) regimen versus the pro re nata (PRN) regimen in patients with bevacizumab-resistant diabetic macular edema (DME) treated with aflibercept, with or without adjunctive laser therapy. Methods Ninety-one eyes from 91 patients who were switched to aflibercept after three consecutive intravitreal bevacizumab injections for the treatment of DME were included in this retrospective real-world study. The patients were categorized into three groups: TAE (n = 30), TAE + laser (n = 31), and PRN (n = 30). Changes in best-corrected visual acuity and central macular subfield thickness (CMST) at 12, 24, and 52 weeks were defined as the primary functional and anatomical outcomes. Results A total of 91 eyes from 91 patients (49.5% female) with a mean age of 63.9 ± 7.1 years were included in the analysis. At 52 weeks, the mean letter gains were 8.03, 8.90, and 10.23 in the TAE, TAE + laser, and PRN groups, respectively. Anatomical improvements, as measured by CMST reduction, were 55.33 µm, 33.35 µm, and 48.96 µm in the TAE, TAE + laser, and PRN groups, respectively. The average number of injections administered was 7.7, 8.1, and 8.1, respectively. The final extension interval for the TAE group was 8.7 weeks, compared to 9.5 weeks in the TAE + laser group. Conclusions The PRN group demonstrated the highest functional improvement while the TAE group showed the greatest anatomical improvement. Overall, both anatomical and functional outcomes in the TAE regimen were comparable to the PRN regimen in patients with bevacizumab-resistant diabetic macular edema. |
| format | Article |
| id | doaj-art-9515c2d0d32147649f26ab8f32941fea |
| institution | Kabale University |
| issn | 2193-8245 2193-6528 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Ophthalmology and Therapy |
| spelling | doaj-art-9515c2d0d32147649f26ab8f32941fea2025-01-12T12:10:42ZengAdis, Springer HealthcareOphthalmology and Therapy2193-82452193-65282024-11-0114116918110.1007/s40123-024-01067-xOne-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World StudyZubeyir Yozgat0Mehmed Ugur Isik1Mehmet Cem Sabaner2Retina Division, Department of Ophthalmology, Kastamonu Training and Research Hospital, Kastamonu UniversityRetina Division, Department of Ophthalmology, Kastamonu Training and Research Hospital, Kastamonu UniversityRetina Division, Department of Ophthalmology, Kastamonu Training and Research Hospital, Kastamonu UniversityAbstract Introduction The aim of this study was to compare the efficacy of the treat-and-extend (TAE) regimen versus the pro re nata (PRN) regimen in patients with bevacizumab-resistant diabetic macular edema (DME) treated with aflibercept, with or without adjunctive laser therapy. Methods Ninety-one eyes from 91 patients who were switched to aflibercept after three consecutive intravitreal bevacizumab injections for the treatment of DME were included in this retrospective real-world study. The patients were categorized into three groups: TAE (n = 30), TAE + laser (n = 31), and PRN (n = 30). Changes in best-corrected visual acuity and central macular subfield thickness (CMST) at 12, 24, and 52 weeks were defined as the primary functional and anatomical outcomes. Results A total of 91 eyes from 91 patients (49.5% female) with a mean age of 63.9 ± 7.1 years were included in the analysis. At 52 weeks, the mean letter gains were 8.03, 8.90, and 10.23 in the TAE, TAE + laser, and PRN groups, respectively. Anatomical improvements, as measured by CMST reduction, were 55.33 µm, 33.35 µm, and 48.96 µm in the TAE, TAE + laser, and PRN groups, respectively. The average number of injections administered was 7.7, 8.1, and 8.1, respectively. The final extension interval for the TAE group was 8.7 weeks, compared to 9.5 weeks in the TAE + laser group. Conclusions The PRN group demonstrated the highest functional improvement while the TAE group showed the greatest anatomical improvement. Overall, both anatomical and functional outcomes in the TAE regimen were comparable to the PRN regimen in patients with bevacizumab-resistant diabetic macular edema.https://doi.org/10.1007/s40123-024-01067-xAfliberceptBevacizumab-resistantDiabetic macular edemaPro re nata regimenReal-world studyTreat-and-extend regimen |
| spellingShingle | Zubeyir Yozgat Mehmed Ugur Isik Mehmet Cem Sabaner One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study Ophthalmology and Therapy Aflibercept Bevacizumab-resistant Diabetic macular edema Pro re nata regimen Real-world study Treat-and-extend regimen |
| title | One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study |
| title_full | One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study |
| title_fullStr | One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study |
| title_full_unstemmed | One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study |
| title_short | One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study |
| title_sort | one year outcomes of aflibercept in treat and extend versus pro re nata regimens for bevacizumab resistant diabetic macular edema a real world study |
| topic | Aflibercept Bevacizumab-resistant Diabetic macular edema Pro re nata regimen Real-world study Treat-and-extend regimen |
| url | https://doi.org/10.1007/s40123-024-01067-x |
| work_keys_str_mv | AT zubeyiryozgat oneyearoutcomesofafliberceptintreatandextendversusprorenataregimensforbevacizumabresistantdiabeticmacularedemaarealworldstudy AT mehmedugurisik oneyearoutcomesofafliberceptintreatandextendversusprorenataregimensforbevacizumabresistantdiabeticmacularedemaarealworldstudy AT mehmetcemsabaner oneyearoutcomesofafliberceptintreatandextendversusprorenataregimensforbevacizumabresistantdiabeticmacularedemaarealworldstudy |